0000899243-18-024796.txt : 20180919 0000899243-18-024796.hdr.sgml : 20180919 20180919194201 ACCESSION NUMBER: 0000899243-18-024796 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180917 FILED AS OF DATE: 20180919 DATE AS OF CHANGE: 20180919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morningside Venture Investments Ltd CENTRAL INDEX KEY: 0001543112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 181078500 BUSINESS ADDRESS: STREET 1: MCCARTHY LEGAL SERVICES STREET 2: 1188 CENTRE STREET CITY: NEWTON CENTRE STATE: MA ZIP: 02459 BUSINESS PHONE: 617-244-2800 MAIL ADDRESS: STREET 1: MCCARTHY LEGAL SERVICES STREET 2: 1188 CENTRE STREET CITY: NEWTON CENTRE STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 BUSINESS PHONE: 502-241-4114 MAIL ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-09-17 0 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001543112 Morningside Venture Investments Ltd 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVENUE DES CITRONNIERS MC 98000 O9 MONACO 0 0 1 0 Common Stock 2018-09-17 4 P 0 31400 18.50 A 11384703 D Common Stock 2018-09-17 4 P 0 8600 18.84 A 11393303 D Common Stock 2018-09-18 4 P 0 40000 18.47 A 11433303 D Common Stock 2018-09-19 4 P 0 60000 18.09 A 11493303 D The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $17.75 to $18.74, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/17/2018 in multiple transactions at prices ranging from $18.75 to $18.99, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/18/2018 in multiple transactions at prices ranging from $18.23 to $18.96, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price is a weighted average price. These shares were purchased on 9/19/2018 in multiple transactions at prices ranging from $17.81 to $18.44, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL. /s/ Louise Mary Garbarino 2018-09-19 /s/ Jill Marie Franklin 2018-09-19